Crisis-free for roughly two years after a single treatment
In the long human struggle against inherited blood disorders, a new chapter is being written for the youngest patients. Vertex Pharmaceuticals has presented early evidence that its CRISPR-based therapy Casgevy can free children as young as five from the relentless pain crises of sickle cell disease and the transfusion dependence of beta thalassemia — conditions that have shaped, and often diminished, childhood for generations. The findings, shared at a major hematology gathering, carry both the weight of genuine hope and the sobering reminder that even transformative medicine carries risk.
- Children as young as five — previously excluded from gene therapy trials — have now been treated with Casgevy, pushing the frontier of CRISPR medicine into its youngest and most vulnerable territory.
- Four sickle cell patients remained free from vaso-occlusive crises for up to two years, and twelve beta thalassemia patients shed their dependence on frequent blood transfusions — outcomes that redefine what these children's lives can look like.
- One child died from pneumonia and multi-organ failure tied to pre-treatment chemotherapy, a stark reminder that the path to a cure runs through dangerous terrain.
- Vertex is moving toward global regulatory filings in early 2025, armed with expedited review status, racing to make the therapy available to younger patients currently locked out by age restrictions.
- The central tension now is whether early trial results will hold at scale, and whether regulatory systems can move with the urgency the science — and the children waiting — demand.
Vertex Pharmaceuticals has announced results from a CRISPR gene therapy trial in children as young as five, the first time a genetic editing treatment has been tested at this age in patients with serious inherited blood disorders. Four children with sickle cell disease who received Casgevy remained free from vaso-occlusive crises — the severe, unpredictable pain episodes that define the disease — for at least a year, with the longest remissions stretching to roughly two years.
A second group of twelve children with transfusion-dependent beta thalassemia became transfusion-free after treatment, some for nearly two years. For these patients, freedom from regular transfusions means freedom from constant hospital visits, the risk of iron overload, and a life organized around a medical supply chain. Casgevy achieves this by using CRISPR technology to edit a patient's own blood cells outside the body before reinfusing them — a process currently approved only for patients twelve and older, making these younger results a meaningful new frontier.
Vertex's Chief Medical Officer called the findings transformative, describing them as the first clinical evidence of any genetic therapy working in this age group for sickle cell disease. The company plans to file for regulatory approval globally in the first half of next year and holds expedited review status from U.S. regulators.
The trial was not without loss. One patient died from pneumonia and multi-organ failure linked to complications from busulfan, the chemotherapy drug used to prepare the body before the gene therapy transplant. The death is a reminder that even the most promising treatments carry serious risks, especially for children navigating intensive medical regimens.
Presented at the American Society of Hematology Annual Meeting, the data raise a question that will define the next chapter: whether these early results will hold as the therapy moves toward broader use, and whether the path through regulators will prove as swift as the science now seems to warrant.
Vertex Pharmaceuticals announced results from its CRISPR gene therapy trial in children as young as five years old, marking the first time a genetic editing treatment has been tested at this age in patients with serious blood disorders. The company presented data showing that four children with sickle cell disease who received Casgevy remained free from vaso-occlusive crises—the severe, debilitating pain episodes that define the disease—for at least a year after treatment. In the longest cases, children stayed crisis-free for roughly two years.
Vaso-occlusive crises occur when sickled red blood cells block blood vessels, causing pain so intense it often requires hospitalization. For children living with sickle cell disease, these episodes are unpredictable and can strike multiple times a year. The ability to eliminate them entirely, even temporarily, represents a fundamental shift in what treatment can offer.
The therapy also showed results in a second patient group. Twelve children with transfusion-dependent beta thalassemia—a separate inherited blood disorder—became transfusion-free after receiving Casgevy, with some remaining free of transfusions for nearly two years. For these patients, the burden of frequent blood transfusions shapes daily life: regular hospital visits, the risk of iron overload in organs, and the constant dependence on a supply chain. Becoming transfusion-free is transformative.
Casgevy works by using CRISPR technology, the Nobel Prize-winning molecular tool that acts like genetic scissors, cutting away faulty sections of DNA and allowing cells to be repaired or replaced with healthy genetic code. The therapy requires extracting a patient's own blood cells, editing them in the laboratory, and then reinfusing them back into the body. It is currently approved only for patients twelve and older, which is why these results in younger children open a new frontier.
Vertex's Chief Medical Officer Carmen Bozic called the findings transformative, noting they represent the first clinical evidence of any genetic therapy working in this age group for sickle cell disease. The company plans to file for regulatory approval globally in the first half of next year and has already received a Commissioner's National Priority Voucher from U.S. regulators, a designation that will speed up the review process.
One patient in the trial died from pneumonia and multi-organ failure stemming from severe liver disease, a complication linked to the chemotherapy drug busulfan used before the gene therapy transplant. The death underscores that even promising treatments carry risks, particularly in the complex medical landscape of children undergoing intensive therapies.
The data were presented at the American Society of Hematology Annual Meeting. If regulatory approval follows, Casgevy could become available to a much younger population of children living with these blood disorders, potentially sparing them years of pain and transfusion dependence. The question now is whether the results will hold as the therapy moves into broader use, and whether the regulatory pathway will move as quickly as the science suggests it should.
Citações Notáveis
These results demonstrate the transformative potential of Casgevy and represent the first clinical data ever presented on any genetic therapy for children ages 5-11 years with sickle cell disease— Carmen Bozic, Vertex Chief Medical Officer
A Conversa do Hearth Outra perspectiva sobre a história
Why does treating five-year-olds matter so much more than treating teenagers?
Because these children have decades of life ahead. A teenager with sickle cell might endure ten or twenty years of crises. A five-year-old could avoid them entirely for their whole childhood, their school years, their adolescence. That's not just medical—that's biographical.
The therapy uses CRISPR. Isn't that still experimental?
It was. But Casgevy is already approved and in use for older patients. What's new here is proving it works safely in younger bodies, where the stakes feel higher and the biology is still developing.
One patient died. How does that factor into "promising"?
It's the hard part of the story. The death was linked to pre-transplant chemotherapy, not the gene therapy itself. But it's a reminder that these are sick children undergoing intensive treatment. Nothing is risk-free.
What does transfusion-free actually mean for a kid?
It means no more regular hospital visits for blood infusions. No more iron building up in the heart and liver. No more depending on blood banks and donor supplies. For a child, that's freedom to be a child—to go to school, play, not organize life around medical appointments.
Why is the expedited review status important?
It compresses the timeline. Instead of waiting years for approval, regulators will prioritize the application. If the data hold up, these children could access the therapy sooner rather than later.
What happens if it doesn't work as well in larger populations?
That's the real test ahead. Four children and twelve children are small numbers. The question is whether the results replicate when thousands of children receive it. That's when you find out if this is truly transformative or just promising.